» Articles » PMID: 19893015

MicroRNA-133a Protects Against Myocardial Fibrosis and Modulates Electrical Repolarization Without Affecting Hypertrophy in Pressure-overloaded Adult Hearts

Overview
Journal Circ Res
Date 2009 Nov 7
PMID 19893015
Citations 187
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: MicroRNA (miR)-133a regulates cardiac and skeletal muscle differentiation and plays an important role in cardiac development. Because miR-133a levels decrease during reactive cardiac hypertrophy, some have considered that restoring miR-133a levels could suppress hypertrophic remodeling.

Objective: To prevent the "normal" downregulation of miR-133a induced by an acute hypertrophic stimulus in the adult heart.

Methods And Results: miR-133a is downregulated in transverse aortic constriction (TAC) and isoproterenol-induced hypertrophy, but not in 2 genetic hypertrophy models. Using MYH6 promoter-directed expression of a miR-133a genomic precursor, increased cardiomyocyte miR-133a had no effect on postnatal cardiac development assessed by measures of structure, function, and mRNA profile. However, increased miR-133a levels increased QT intervals in surface electrocardiographic recordings and action potential durations in isolated ventricular myocytes, with a decrease in the fast component of the transient outward K+ current, I(to,f), at baseline. Transgenic expression of miR-133a prevented TAC-associated miR-133a downregulation and improved myocardial fibrosis and diastolic function without affecting the extent of hypertrophy. I(to,f) downregulation normally observed post-TAC was prevented in miR-133a transgenic mice, although action potential duration and QT intervals did not reflect this benefit. miR-133a transgenic hearts had no significant alterations of basal or post-TAC mRNA expression profiles, although decreased mRNA and protein levels were observed for the I(to,f) auxiliary KChIP2 subunit, which is not a predicted target.

Conclusions: These results reveal striking differences between in vitro and in vivo phenotypes of miR expression, and further suggest that mRNA signatures do not reliably predict either direct miR targets or major miR effects.

Citing Articles

MicroRNA-26b inhibits cardiac remodeling after myocardial infarction by targeting ring finger protein 6 expression.

Tang C, Su Q, Zhao H, Sui H, Liang J, Zhu L Arch Med Sci. 2025; 20(6):2009-2021.

PMID: 39967940 PMC: 11831335. DOI: 10.5114/aoms/130649.


Integrated analysis of long non‑coding RNA megacluster, microRNA‑132 and microRNA‑133a and their implications for cardiovascular risk and kidney failure progression in diabetic patients.

AbdElgayed G, Hosni A, Abdel-Moneim A, Malik A, Zaky M, Hasona N Exp Ther Med. 2025; 29(2):35.

PMID: 39776891 PMC: 11705225. DOI: 10.3892/etm.2024.12785.


MicroRNA and Heart Failure: A Novel Promising Diagnostic and Therapeutic Tool.

DAmato A, Prosperi S, Severino P, Myftari V, Correale M, Filardi P J Clin Med. 2025; 13(24.

PMID: 39768484 PMC: 11728316. DOI: 10.3390/jcm13247560.


Isoproterenol mechanisms in inducing myocardial fibrosis and its application as an experimental model for the evaluation of therapeutic potential of phytochemicals and pharmaceuticals.

Bader Eddin L, Nagoor Meeran M, Jha N, Goyal S, Ojha S Animal Model Exp Med. 2024; 8(1):67-91.

PMID: 39690876 PMC: 11798751. DOI: 10.1002/ame2.12496.


Exploring the role of non-coding RNAs in atrial septal defect pathogenesis: A systematic review.

Amirsardari Z, Gholipour A, Khajali Z, Maleki M, Malakootian M PLoS One. 2024; 19(8):e0306576.

PMID: 39172906 PMC: 11340980. DOI: 10.1371/journal.pone.0306576.


References
1.
Van Rooij E, Olson E . MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest. 2007; 117(9):2369-76. PMC: 1952642. DOI: 10.1172/JCI33099. View

2.
Kuo H, Cheng C, Clark R, Lin J, Lin J, Hoshijima M . A defect in the Kv channel-interacting protein 2 (KChIP2) gene leads to a complete loss of I(to) and confers susceptibility to ventricular tachycardia. Cell. 2001; 107(6):801-13. DOI: 10.1016/s0092-8674(01)00588-8. View

3.
Guo W, Xu H, London B, Nerbonne J . Molecular basis of transient outward K+ current diversity in mouse ventricular myocytes. J Physiol. 1999; 521 Pt 3:587-99. PMC: 2269690. DOI: 10.1111/j.1469-7793.1999.00587.x. View

4.
Ikeda S, Kong S, Lu J, Bisping E, Zhang H, Allen P . Altered microRNA expression in human heart disease. Physiol Genomics. 2007; 31(3):367-73. DOI: 10.1152/physiolgenomics.00144.2007. View

5.
Luo X, Lin H, Pan Z, Xiao J, Zhang Y, Lu Y . Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. J Biol Chem. 2008; 283(29):20045-52. DOI: 10.1074/jbc.M801035200. View